ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Dual-targeted protein-coated PLGA nanoparticles for pancreatic cancer therapy: a novel approach using esculetin and curcumin.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Esculetin induces apoptosis and functional impairment in INS-1 pancreatic β-cells associated with ER stress and MAPK/JNK signaling.Protoplasma · 2026Article
- Therapeutic Advances of Curcumin and Nanocurcumin in Glioblastoma: Molecular Targets, Bioavailability, and Drug Delivery.Nutrients · 2026Review
- PLGA-based nanoparticles in colorectal cancer immunotherapy: current concepts and future perspectives.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The study aimed to investigate the effects of dual-targeted poly-lactic-co-glycolic acid (PLGA) nanoparticles (NP) containing esculetin (ESC) and curcumin (CURC), coated with membrane and cytosolic proteins, isolated from PID-PC (pancreatic islet-derived precursor cells) and MIA PaCa-2 cells, on pancreatic cancer. MIA PaCa-2 cells' viability treated with different combinations of the above-mentioned molecules and proteins was investigated in vitro. The sizes of all formed nanoparticles were determined by the "dynamic light scattering" method. The drug release profile of drug-containing PLGA-NP was examined. Cell death percentages and ROS levels were analyzed. Naked ESC showed an IC50 of 45.226 µg, while PLGA-coated ESC showed no measurable IC50. For CURC, no IC50 was observed in its naked form, but PLGA-CURC induced cell death starting at 6.25 µg. In the PLGA_ESC + CURC group, IC50 values were 75 µg for ESC and 9.375 µg for CURC. PLGA-coated PID-PC cytoplasmic proteins reduced ESC-treated cell viability by 46.42%, while the PLGA-coated MIA PaCa-2 cytoplasmic protein with ESC + CURC was most effective (41.11%). PLGA_ESC was released in 48 h, but protein coating accelerated release to 6 h. CURC showed delayed release, reaching only 30% at 72 h. PID-PC membrane proteins enhanced and prolonged release; MIA PaCa-2 cytoplasmic proteins suppressed it. Necrosis increased in all groups, while apoptosis and ROS decreased except in the CURC-treated groups. The novel membrane and cytosolic protein-coated PLGA-NP designed by our group, for the first time, has provided significant results in the treatment of pancreatic cancer.
Indexed as
Identifiers
40694096What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.